Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist.

Date publication

juillet 2014

Journal

Circulation. Heart failure

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick

Tous les auteurs :
Vardeny O, Claggett B, Anand I, Rossignol P, Desai AS, Zannad F, Pitt B, Solomon SD,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/24812304

Résumé

Mineralocorticoid receptor antagonists reduce morbidity and mortality in patients with heart failure but can cause hyperkalemia, which contributes to reduced use of these drugs. Hypokalemia also leads to worse outcomes in patients with heart failure and may be attenuated by mineralocorticoid receptor antagonists.

Mots clés

Cause of Death, trends, Dose-Response Relationship, Drug, Double-Blind Method, Echocardiography, Follow-Up Studies, Global Health, Heart Failure, diagnostic imaging, Heart Ventricles, diagnostic imaging, Hyperkalemia, blood, Hypokalemia, blood, Incidence, Mineralocorticoid Receptor Antagonists, administration & dosage, Potassium, blood, Retrospective Studies, Risk Factors, Severity of Illness Index, Spironolactone, administration & dosage, Stroke Volume, Survival Rate, trends, Treatment Outcome, Ventricular Function, Left, drug effects

Référence

Circ Heart Fail. 2014 Jul;7(4):573-9